Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

NCT04397510 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-04-03

No results posted yet for this study

Summary

Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19

Conditions

  • Covid-19
  • ARDS, Human
  • Acute Lung Injury

Interventions

DRUG

Heparin

Nebulized Heparin

DRUG

0.9% Sodium-chloride

Nebulized 0.9% Sodium Chloride

Sponsors & Collaborators

  • Frederick Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397510 on ClinicalTrials.gov